Cingulate (CING) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 05, 2022
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-40874
Entity Registrant Name	Cingulate Inc.
Entity Central Index Key	0001862150
Entity Tax Identification Number	86-3825535
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1901 W. 47th Place
Entity Address, City or Town	Kansas City
Entity Address, State or Province	KS
Entity Address, Postal Zip Code	66205
City Area Code	(913)
Local Phone Number	942-2300
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		11,309,412
Common Stock, par value $0.0001 per share
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	CING
Security Exchange Name	NASDAQ
Warrants, exercisable for one share of common stock
Title of 12(b) Security	Warrants, exercisable for one share of common stock
Trading Symbol	CINGW
Security Exchange Name	NASDAQ

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 12,614,180	$ 16,492,745
Short-term investments	933	933
Miscellaneous receivables	651,371	690,248
Prepaid expenses and other current assets	1,307,137	1,698,353
Total current assets	14,573,621	18,882,279
Property and equipment, net	3,054,349	3,145,378
Operating lease right-of-use assets	804,711	858,600
Total assets	18,432,681	22,886,257
Current liabilities:
Accounts payable	556,326	264,687
Accrued expenses	756,035	601,300
Current installments of obligations under finance leases	15,335	15,096
Other current liabilities	303,263	295,595
Total current liabilities	1,630,959	1,176,678
Long-term liabilities:
Obligations under finance leases	33,613	37,534
Operating lease liabilities	749,508	828,503
Total liabilities	2,414,080	2,042,715
Stockholders’ Equity
Common Stock, $0.0001 par value; 240,000,000 shares authorized and 11,309,412 shares issued and outstanding as of March 31, 2022 and December 31, 2021	1,131	1,131
Preferred Stock, $0.0001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding as of December 31, 2021
Additional Paid-in-Capital	72,756,028	72,574,510
Accumulated other comprehensive income	(2,783)	165
Accumulated deficit	(56,735,775)	(51,732,264)
Total stockholders’ equity	16,018,601	20,843,542
Total liabilities and stockholders’ equity	$ 18,432,681	$ 22,886,257

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical)	Dec. 31, 2021$ / sharesshares
Statement of Financial Position [Abstract]
Common stock, par value | $ / shares	$ 0.0001
Common stock, shares authorized	240,000,000
Common stock, shares issued	11,309,412
Common stock, shares outstanding	11,309,412
Preferred stock, par value | $ / shares	$ 0.0001
Preferred stock, shares authorized	10,000,000
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 2,762,284	$ 562,519
General and administrative	2,247,060	767,645
Operating loss	(5,009,344)	(1,330,164)
Interest and other income (expense), net	5,833	(3,759)
Loss before income taxes	(5,003,511)	(1,333,923)
Income tax benefit (expense)
Net loss	(5,003,511)	(1,333,923)
Other comprehensive income (loss):
Change in unrealized gain on short-term investments	(2,948)
Comprehensive loss	$ (5,006,459)	$ (1,333,923)
Net loss per share of common stock, basic and diluted	$ (0.44)
Weighted average number of shares used in computing net loss per share of common stock, basic and diluted	11,309,412

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Members Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Dec. 31, 2020			$ 32,314,441	$ (31,022,336)	$ 165	$ 1,292,270
Beginning balance, shares at Dec. 31, 2020
Member contributions			1,385,688			1,385,688
Net loss				(1,333,923)		(1,333,923)
Ending balance, value at Mar. 31, 2021			33,700,129	(32,356,259)	165	1,344,035
Ending balance, shares at Mar. 31, 2021
Beginning balance, value at Dec. 31, 2021	$ 1,131	72,574,510		(51,732,264)	165	20,843,542
Beginning balance, shares at Dec. 31, 2021	11,309,412
Net loss				(5,003,511)		(5,003,511)
Unrealized losses on available for sale investments					(2,948)	(2,948)
Stock-based compensation expense		181,518				181,518
Ending balance, value at Mar. 31, 2022	$ 1,131	$ 72,756,028		$ (56,735,775)	$ (2,783)	$ 16,018,601
Ending balance, shares at Mar. 31, 2022	11,309,412

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities:
Net loss	$ (5,003,511)	$ (1,333,923)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	101,429	174,698
Stock-based compensation	181,518
Other	(2,948)
Changes in operating assets and liabilities:
Miscellaneous receivables	38,877	(54,128)
Prepaid expenses and other current assets	391,216	(187,294)
Operating lease right-of-use assets	53,889	(49,826)
Trade accounts payable and accrued expenses	446,374	(257,690)
Other current liabilities	7,668	38,833
Operating lease liabilities	(78,995)	(4,669)
Net cash used in operating activities	(3,864,483)	(1,673,999)
Investing activities:
Purchase of property and equipment	(10,400)	(66,469)
Net cash used in investing activities	(10,400)	(66,469)
Financing Activities:
Members’ capital contributions		1,385,688
Proceeds from notes payable		69,789
Principal payments on finance lease obligations	(3,682)	(104,438)
Net cash provided by financing activities	(3,682)	1,351,039
Cash and cash equivalents:
Net increase in cash and cash equivalents	(3,878,565)	(389,429)
Cash and cash equivalents at beginning of year	16,492,745	1,197,672
Cash and cash equivalents at end of year	12,614,180	808,243
Non-cash activities
Property and equipment accrued but not yet paid at end of period	10,400
Cash payments:
Interest paid	$ 793	$ 3,075

Nature of the Business and Liqu

Nature of the Business and Liquidity	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Nature of the Business and Liquidity	(1) Nature of the Business and Liquidity Organization Cingulate Inc. is a clinical stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. CTx-1301 and CTx-1302 utilize a flexible core tableting technology with target product profile designed to deliver a rapid onset and last the entire active day with a controlled descent of plasma drug level and have favorable tolerability. The Company is preparing to start Phase 3 clinical trials for CTx-1301 in the second half of 2022. In addition, the Company has a third product to treat anxiety, CTx-2103, in a proof-of-concept stage. On November 14, 2012, Cingulate Therapeutics LLC (CTx), a Delaware limited liability company, was formed. On May 10, 2021, Cingulate Inc. (Cingulate, or the Company), a Delaware corporation and wholly-owned subsidiary of CTx, was formed to serve as a holding company, in anticipation of the Company becoming publicly traded. Through a Reorganization Merger which occurred in the third quarter of 2021, Cingulate effectively acquired CTx and all outstanding units of CTx were converted into shares of Cingulate common stock. CTx remains the entity through which the Company conducts operations. CTx is the predecessor of Cingulate for financial reporting purposes. The consolidated financial statements and notes for the year ended December 31, 2021 represent the full consolidation of Cingulate and its subsidiaries, including CTx and all references to the Company represent this full consolidation. For periods prior to the year ended December 31, 2021, the consolidated financial statements and notes represent the full consolidation of CTx and its subsidiaries. Liquidity The Company has incurred losses and negative cash flows from operations since inception. As a pre-revenue entity, the Company is dependent on the ability to raise capital to support operations until such time as the product candidates under development are U.S. Food and Drug Administration (FDA) approved, manufactured, commercially available to the marketplace and produce revenues. The IPO, which was completed in December 2021, provided the Company the ability to continue its research and development activities; however, the Company will need additional funding for operations and development in order to meet its obligations in the longer term. Management is evaluating various strategies to obtain additional funding for operations and development beyond that time which may include additional offerings of common stock, issuance of debt, potential strategic research and development partners, and licensing and/or marketing arrangements with pharmaceutical companies. Successful implementation of these plans involves both the Company’s efforts and factors that are outside its control, such as market factors and FDA approval of product candidates. The Company can give no assurance that its plans will be effectively implemented in such a way that they will sufficiently alleviate or mitigate the conditions and events noted above, which results in substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies (a) Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of Cingulate and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. (b) Unaudited Interim Financial Information The accompanying consolidated balance sheet as of March 31, 2022, the consolidated statements of operations for the three months ended March 31, 2022 and 2021, the consolidated statement of stockholders’ equity for the three-month periods ended March 31, 2022 and 2021, the consolidated statements of cash flows for the three months ended March 31, 2022 and 2021, and the related interim disclosures are unaudited. These unaudited consolidated financial statements include all adjustments necessary, consisting of only normal recurring adjustments, to fairly state the financial position and the results of operations and cash flows for interim periods in accordance with U.S. GAAP. Interim period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto. (c) Concentration of Credit Risk The Company maintains cash equivalent deposits, which at various times throughout the fiscal year exceeded the amounts insured by the Federal Deposit Insurance Corporation limit of $ 250,000 (d) Miscellaneous Receivables Miscellaneous receivables consist of payroll tax credits generated from the Company’s 2020 and 2019 federal income tax returns, which have not yet been received as of March 31, 2022, as well as employee retention tax credits for payroll costs incurred in 2020 and the first three quarters of 2021. As of March 31, 2022 and December 31, 2021, the Company determined that there was no allowance necessary relating to these receivables. (e) Impairment of Long-lived Assets The Company assesses the carrying value of its long-lived assets, including property and equipment, as well as lease ROU assets, when events or circumstances indicate that the carrying value of such assets may not be recoverable. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by a comparison of the carrying amount of the assets to future undiscounted cash flows expected to be generated by the assets. If the sum of the expected future cash flows is less than the carrying amount, the Company would recognize an impairment loss. An impairment loss would be measured by comparing the amount by which the carrying value exceeds the fair value of the long-lived asset groups. No (f) Stock-Based Compensation The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. See additional information in Note 9.

Fair Value of Assets and Liabil

Fair Value of Assets and Liabilities	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Assets and Liabilities	(3) Fair Value of Assets and Liabilities The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair values based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: Level 1 Level 2 Level 3 The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Company’s policy is to recognize significant transfers between the levels at the actual date of the event. There were no transfers in or out of Levels 1, 2, or 3 during the three months ended March 31, 2022 or March 31, 2021. The Company has no Level 2 or Level 3 investments. The cash and short-term investments held by the Company are categorized as Level 1 investments as quoted market prices are readily available for these investments. Assets measured and carried at fair value on a recurring basis are summarized below: Schedule of Assets Measured and Carried at Fair Value on Recurring Basis March 31, 2022 Fair Fair Fair Amortized Gross Unrealized Gross Unrealized Value of Current Value of Non-Current Value of Total Cost Gains Losses Assets Assets Assets Money Market Fund $ 12,003,223 - $ (2,949 ) - - $ 12,000,274 Equity investments Mutual funds 933 - - - - 933 Total $ 12,004,156 $ - $ (2,949 ) $ - $ - $ 12,001,207 December 31, 2021 Fair Fair Fair Amortized Gross Unrealized Gross Unrealized Value of Current Value of Non-Current Value of Total Cost Gains Losses Assets Assets Assets Equity investments Mutual Funds $ 920 $ - $ - $ - $ - $ 933

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	(4) Property and Equipment Property and equipment, net consists of the following at March 31, 2022 and December 31, 2021: Schedule of Property and Equipment Estimated Useful Life March 31, December 31, (in years) 2022 2021 Equipment 2 7 $ 2,509,126 $ 2,509,126 Furniture and fixtures 7 145,754 145,754 Computer equipment 5 41,898 41,898 Leasehold improvements 5 471,505 471,505 Construction-in-process - 1,653,550 1,643,150 Property and equipment, gross 4,821,833 4,811,433 Less: accumulated depreciation (1,767,484 ) (1,666,055 ) Property and equipment, net $ 3,054,349 $ 3,145,378 Depreciation expense for the three months ended March 31, 2022 was $ 101,429 174,698

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses	(5) Accrued Expenses Accrued expenses consisted of the following at March 31, 2022 and December 31, 2021: Schedule of Accrued Expenses March 31, December 31, 2022 2021 Professional and consulting fees $ 280,500 $ 15,000 Research and development 405,000 250,000 CIP- Equipment - 279,730 Other 70,535 56,570 Accrued Expenses $ 756,035 $ 601,300

Members_ Capital

Members’ Capital	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Members’ Capital	(6) Members’ Capital Prior to the Reorganization Merger, the Company had multiple classes of Members’ capital, comprised of Founders Units, Class B, D, E, F and G Preferred Units, and Class C Profits Interests. Class B, E, F and G Preferred Units had similar rights specifically related to cash distributions as a return of invested capital. Class D Preferred Units had all the rights of Founders and the other Classes of Preferred Units plus some additional rights noted below. All classes of Members’ capital had voting rights. The Company maintained capital accounts for each Member. 3,243,201 614,137 Class F Preferred Units The CTx Board authorized 6,984,985 11.3 rd Class G Preferred Units The CTx Board authorized 12,000,000 2,998,184 6.7 Distributions, if any, from the Company were to be made first to the holders of Class B, D, E, F and G Preferred Units, pro rata in proportion to each such Member’s unreturned capital contributions. Distributions were then to be made to all Members including Founders Units, pro rata in proportion to the number of units held by each Member, with consideration given to the applicable distribution thresholds for Class C Profits Interests at which each was issued and as disclosed in each Profits Interest Unit agreement, as further described in Note 7. Costs associated with issuance of the Units is immaterial. Pursuant to the terms of the Reorganization Merger, all Units were converted into shares of common stock of Cingulate, as further described in Note 1.

Profits Interest Plan

Profits Interest Plan	3 Months Ended
	Mar. 31, 2022
Retirement Benefits [Abstract]
Profits Interest Plan	(7) Profits Interest Plan During 2017, the CTx Board established and adopted the Cingulate Therapeutics LLC Equity Incentive Plan (the “Plan”) to provide for issuance of Class C PIU’s to employees, CTx Members, Board members and service providers of the Company, as defined in the Plan, eligible to receive PIU’s as an incentive under the Plan. PIU’s were granted at the discretion of the Board of Managers of the Company and in some cases at the discretion of the Chief Executive Officer of the Company based upon Board authorization. The PIU’s were issued at a Distribution Threshold equal to the pre-money fair market valuation of the Company at the date of issuance. The Distribution Threshold was the amount by which a cash distribution, made pro rata to all Members, if any, must have been exceeded in order for a particular PIU holder to participate in the allocated distribution beyond that threshold. Based on the terms of the award, the Distribution Threshold was treated as a performance condition for purposes of financial statement recognition. The PIU’s vesting period with respect to the service condition was defined in the PIU award agreement and ranged from 30 days to three years with an average vesting period for all PIU’s granted of 107 Immediately prior to the Reorganization Merger and as of December 31, 2020, the Company had granted and issued 8,500,000 8,142,461 357,539 , Compensation – Stock Compensation, 8.5 1,158,008 12.7 8.2 4.5 Prior to the Reorganization Merger, the Company had issued all units available under the Plan and all units had vested based upon the vesting period as outlined in the PIU agreement. PIUs issued and outstanding prior to the Reorganization Merger, which was also the modification date, at the various distribution thresholds were as follows: Schedule of Various Distribution Thresholds Distribution Threshold $ (in millions): Year Granted $25 $40 $75 $80 $90 $120 $160 Total 2017 4,753,000 125,200 - - - - - 4,878,200 2018 - 661,525 217,725 22,883 - - - 902,133 2019 - - - - 377,524 458,924 - 836,448 2020 - - - 1,476,126 - 49,554 - 1,525,680 2021 357,539 357,539 Total 4,753,000 786,725 217,725 1,499,009 377,524 508,478 357,539 8,500,000

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders’ Equity	(8) Stockholders’ Equity The Company has authorized 240,000,000 0.0001 10,000,000 0.0001 11,309,412 7,142,746 4,166,666 6.00 20.4 The holders of common stock are entitled to one vote for each share of common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution, if any. Holders of the shares of common stock are entitled to dividends when and if declared by the Board of Directors.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	(9) Stock-Based Compensation In September 2021, the Company’s board of directors and stockholders adopted the 2021 Equity Incentive Plan (the “2021 Plan”), which provides for the grant of incentive stock options and non-qualified stock options to purchase shares of the Company’s common stock, stock appreciation rights, restricted stock units, restricted or unrestricted shares of common stock, performance shares, performance units, incentive bonus awards, other stock-based awards and other cash-based awards. No awards may be made under the 2021 Plan on or after September 24, 2031, but the 2021 Plan will continue thereafter while previously granted awards remain outstanding. The maximum number of shares of common stock available for issuance in connection with options and other awards granted under the 2021 Plan is 1,927,810 1,061,526 The number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1st of each year until the expiration of the 2021 Plan, in an amount equal to 5% percent of the total number of shares of our common stock outstanding on December 31st of the preceding calendar year, on a fully diluted basis, unless the board of directors takes action prior thereto to provide that there will not be an increase in the share reserve for such year or that the increase in the share reserve for such year will be of a lesser number of shares of common stock than would otherwise occur. The Company recorded stock-based compensation expense of $ 181,518 2,854,519 2,637,895 A summary of option activity under the Plan during the three months ended March 31, 2022 is as follows: Summary of Option Activity Weighted-Average Weighted-Average Aggregate Shares Exercise Price per Share Remaining Contractual Term Intrinsic Value Outstanding at December 31, 2021 523,285 $ 6.00 9.94 Grants 342,999 $ 1.82 9.91 Exercised — Forfeitures or expirations — Outstanding at March 31, 2022 866,284 $ 4.35 9.78 $ 182,900 Vested and expected to vest at March 31, 2022 - Exercisable at March 31, 2022 - The Company’s stock options issued qualify for equity accounting treatment under ASC 718 and are measured at fair value as of their grant date accordingly. The fair value of the options were estimated using a Black-Scholes model. The assumptions that the Company used to estimate the grant-date fair value of stock options granted to employees and directors were as follows: Schedule of Fair Value Assumption March 31, 2022 Risk-free interest rate 1.54 % Weighted-average expected term (in years) 6.0 Expected volatility 1.12 Expected dividend yield 0 % Risk-Free Interest Rate Expected Term: Expected Volatility Expected Dividend Yield The grant-date fair value of options granted during the year ended December 31, 2021 was $ 5.09 1.12 1.16 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock. The fair value per share of common stock was $ 1.97

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	(10) Income Taxes Cingulate Inc. is taxed as a C corporation under the Internal Revenue Code. Cingulate Inc. records deferred income taxes to reflect the impact of temporary differences between the recorded amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. CTx is a wholly-owned disregarded entity of Cingulate Inc., and all of the activity for CTx, along with its wholly-owned subsidiary Cingulate Works Inc., is included in the calculation of the current and deferred tax assets and liabilities for Cingulate Inc. No Income tax expense differed from the expected expense computed by applying the U.S. Federal income tax rate as follows: Schedule of Effective Income Tax Rate Reconciliation Three Months Ended March 31, 2022 Federal income tax benefit at statutory rate $ (1,039,582 ) State income tax benefit (273,757 ) Permanent differences 5,665 Change in valuation allowance 1,361,886 Other (54,212 ) Total income tax expense $ - Evaluating the need for, and amount of, a valuation allowance for deferred tax assets often requires significant judgment and extensive analysis of all available evidence on a jurisdiction-by-jurisdiction basis. Such judgments require the Company to interpret existing tax law and other published guidance as applied to its circumstances. As part of this assessment, the Company considers both positive and negative evidence about its profitability and tax situation. A valuation allowance is provided if, based on available evidence, it is more likely than not that all or some portion of a deferred tax asset will not be realized. The Company determined that it was more likely than not that it would not realize its deferred tax assets, based on historical levels of income and future forecasts of taxable income, among other items. The Company recorded a valuation allowance of its net deferred tax assets totaling $ 2,209,156 847,269 The Company files income tax returns in the U.S. federal and various state jurisdictions. The Companies are not subject to U.S. federal and state income tax examinations by tax authorities for years before 2018. The Company follows the provisions of FASB ASC 740, Income Taxes Schedule of Deferred Tax Assets and Liabilities March 31, 2022 December 31, 2021 Deferred income tax assets: Current: Research and development costs $ 569,826 $ - Unvested stock options 119,333 11,835 Other - 4,050 Non-current: Patents 99,580 90,480 Net operating losses 1,824,223 1,201,974 Other 80,190 49,606 Gross deferred income tax assets 2,693,152 1,357,945 Less: valuation allowance (2,209,156 ) (847,269 ) Net deferred income tax asset 483,996 510,676 Deferred income tax liabilities: Current: Accrual to cash (105,778 ) (105,075 ) Non-current Property and equipment (378,218 ) (405,601 ) Gross deferred income tax liabilities (483,996 ) (510,676 ) Net deferred tax asset (liability) $ - $ -

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	(11) Net Loss Per Share The following table sets forth the computation of the basic and diluted net loss per share for the three months ended March 31, 2022: Schedule of Net Loss Per Share Basic And Diluted Numerator: Net loss $ (5,003,511 ) Denominator: Weighted average common shares outstanding 11,309,412 Net loss per share, basic and diluted $ (0.44 ) Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows as of March 31, 2022: Schedule of Potentially Dilutive Securities Stock options issued under the 2021 Equity Incentive Plan 866,284 Common stock purchase warrants outstanding 4,999,998 Total 5,866,282

License Agreement

License Agreement	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License Agreement	(12) License Agreement CTx has a licensing agreement with a company related to the patents and licensed know-how for use in the development of CTx-1301, CTx-1302, and CTx-2103. CTx will pay the following upon the occurrence of the following milestone events: ● $ 250,000 ● $ 250,000 ● $ 250,000 500,000 ● $ 250,000 The Company has accrued the $ 250,000

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	(13) Related Party Transactions The general counsel of the Company is a partner with a law firm providing office facilities space that is leased by the Company. Rental expense incurred by the Company to the law firm was $ 9,000

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	(14) Subsequent Events Management evaluated events that occurred subsequent to March 31, 2022 through May 12, 2022, which is the date the interim financial statements were issued.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	(a) Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of Cingulate and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Unaudited Interim Financial Information	(b) Unaudited Interim Financial Information The accompanying consolidated balance sheet as of March 31, 2022, the consolidated statements of operations for the three months ended March 31, 2022 and 2021, the consolidated statement of stockholders’ equity for the three-month periods ended March 31, 2022 and 2021, the consolidated statements of cash flows for the three months ended March 31, 2022 and 2021, and the related interim disclosures are unaudited. These unaudited consolidated financial statements include all adjustments necessary, consisting of only normal recurring adjustments, to fairly state the financial position and the results of operations and cash flows for interim periods in accordance with U.S. GAAP. Interim period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto.
Concentration of Credit Risk	(c) Concentration of Credit Risk The Company maintains cash equivalent deposits, which at various times throughout the fiscal year exceeded the amounts insured by the Federal Deposit Insurance Corporation limit of $ 250,000
Miscellaneous Receivables	(d) Miscellaneous Receivables Miscellaneous receivables consist of payroll tax credits generated from the Company’s 2020 and 2019 federal income tax returns, which have not yet been received as of March 31, 2022, as well as employee retention tax credits for payroll costs incurred in 2020 and the first three quarters of 2021. As of March 31, 2022 and December 31, 2021, the Company determined that there was no allowance necessary relating to these receivables.
Impairment of Long-lived Assets	(e) Impairment of Long-lived Assets The Company assesses the carrying value of its long-lived assets, including property and equipment, as well as lease ROU assets, when events or circumstances indicate that the carrying value of such assets may not be recoverable. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by a comparison of the carrying amount of the assets to future undiscounted cash flows expected to be generated by the assets. If the sum of the expected future cash flows is less than the carrying amount, the Company would recognize an impairment loss. An impairment loss would be measured by comparing the amount by which the carrying value exceeds the fair value of the long-lived asset groups. No
Stock-Based Compensation	(f) Stock-Based Compensation The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. See additional information in Note 9.

Fair Value of Assets and Liab_2

Fair Value of Assets and Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Assets Measured and Carried at Fair Value on Recurring Basis	Assets measured and carried at fair value on a recurring basis are summarized below: Schedule of Assets Measured and Carried at Fair Value on Recurring Basis March 31, 2022 Fair Fair Fair Amortized Gross Unrealized Gross Unrealized Value of Current Value of Non-Current Value of Total Cost Gains Losses Assets Assets Assets Money Market Fund $ 12,003,223 - $ (2,949 ) - - $ 12,000,274 Equity investments Mutual funds 933 - - - - 933 Total $ 12,004,156 $ - $ (2,949 ) $ - $ - $ 12,001,207 December 31, 2021 Fair Fair Fair Amortized Gross Unrealized Gross Unrealized Value of Current Value of Non-Current Value of Total Cost Gains Losses Assets Assets Assets Equity investments Mutual Funds $ 920 $ - $ - $ - $ - $ 933

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consists of the following at March 31, 2022 and December 31, 2021: Schedule of Property and Equipment Estimated Useful Life March 31, December 31, (in years) 2022 2021 Equipment 2 7 $ 2,509,126 $ 2,509,126 Furniture and fixtures 7 145,754 145,754 Computer equipment 5 41,898 41,898 Leasehold improvements 5 471,505 471,505 Construction-in-process - 1,653,550 1,643,150 Property and equipment, gross 4,821,833 4,811,433 Less: accumulated depreciation (1,767,484 ) (1,666,055 ) Property and equipment, net $ 3,054,349 $ 3,145,378

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following at March 31, 2022 and December 31, 2021: Schedule of Accrued Expenses March 31, December 31, 2022 2021 Professional and consulting fees $ 280,500 $ 15,000 Research and development 405,000 250,000 CIP- Equipment - 279,730 Other 70,535 56,570 Accrued Expenses $ 756,035 $ 601,300

Profits Interest Plan (Tables)

Profits Interest Plan (Tables)	3 Months Ended
	Mar. 31, 2022
Retirement Benefits [Abstract]
Schedule of Various Distribution Thresholds	PIUs issued and outstanding prior to the Reorganization Merger, which was also the modification date, at the various distribution thresholds were as follows: Schedule of Various Distribution Thresholds Distribution Threshold $ (in millions): Year Granted $25 $40 $75 $80 $90 $120 $160 Total 2017 4,753,000 125,200 - - - - - 4,878,200 2018 - 661,525 217,725 22,883 - - - 902,133 2019 - - - - 377,524 458,924 - 836,448 2020 - - - 1,476,126 - 49,554 - 1,525,680 2021 357,539 357,539 Total 4,753,000 786,725 217,725 1,499,009 377,524 508,478 357,539 8,500,000

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Option Activity	A summary of option activity under the Plan during the three months ended March 31, 2022 is as follows: Summary of Option Activity Weighted-Average Weighted-Average Aggregate Shares Exercise Price per Share Remaining Contractual Term Intrinsic Value Outstanding at December 31, 2021 523,285 $ 6.00 9.94 Grants 342,999 $ 1.82 9.91 Exercised — Forfeitures or expirations — Outstanding at March 31, 2022 866,284 $ 4.35 9.78 $ 182,900 Vested and expected to vest at March 31, 2022 - Exercisable at March 31, 2022 -
Schedule of Fair Value Assumption	The Company’s stock options issued qualify for equity accounting treatment under ASC 718 and are measured at fair value as of their grant date accordingly. The fair value of the options were estimated using a Black-Scholes model. The assumptions that the Company used to estimate the grant-date fair value of stock options granted to employees and directors were as follows: Schedule of Fair Value Assumption March 31, 2022 Risk-free interest rate 1.54 % Weighted-average expected term (in years) 6.0 Expected volatility 1.12 Expected dividend yield 0 %

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	Income tax expense differed from the expected expense computed by applying the U.S. Federal income tax rate as follows: Schedule of Effective Income Tax Rate Reconciliation Three Months Ended March 31, 2022 Federal income tax benefit at statutory rate $ (1,039,582 ) State income tax benefit (273,757 ) Permanent differences 5,665 Change in valuation allowance 1,361,886 Other (54,212 ) Total income tax expense $ -
Schedule of Deferred Tax Assets and Liabilities	Schedule of Deferred Tax Assets and Liabilities March 31, 2022 December 31, 2021 Deferred income tax assets: Current: Research and development costs $ 569,826 $ - Unvested stock options 119,333 11,835 Other - 4,050 Non-current: Patents 99,580 90,480 Net operating losses 1,824,223 1,201,974 Other 80,190 49,606 Gross deferred income tax assets 2,693,152 1,357,945 Less: valuation allowance (2,209,156 ) (847,269 ) Net deferred income tax asset 483,996 510,676 Deferred income tax liabilities: Current: Accrual to cash (105,778 ) (105,075 ) Non-current Property and equipment (378,218 ) (405,601 ) Gross deferred income tax liabilities (483,996 ) (510,676 ) Net deferred tax asset (liability) $ - $ -

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share Basic And Diluted	The following table sets forth the computation of the basic and diluted net loss per share for the three months ended March 31, 2022: Schedule of Net Loss Per Share Basic And Diluted Numerator: Net loss $ (5,003,511 ) Denominator: Weighted average common shares outstanding 11,309,412 Net loss per share, basic and diluted $ (0.44 )
Schedule of Potentially Dilutive Securities	Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows as of March 31, 2022: Schedule of Potentially Dilutive Securities Stock options issued under the 2021 Equity Incentive Plan 866,284 Common stock purchase warrants outstanding 4,999,998 Total 5,866,282

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accounting Policies [Abstract]
Federal deposit insurance corporation limit	$ 250,000
Impairment of long lived assets	$ 0	$ 0

Schedule of Assets Measured and

Schedule of Assets Measured and Carried at Fair Value on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	$ 12,004,156
Gross Unrealized Gain
Gross Unrealized Loss	(2,949)
Fair Value of Current Assets
Fair Value of Non-Current Assets
Fair Value of Total Assets	12,001,207
Money Market Fund [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	12,003,223
Gross Unrealized Gain
Gross Unrealized Loss	(2,949)
Fair Value of Current Assets
Fair Value of Non-Current Assets
Fair Value of Total Assets	12,000,274
Mutual Fund [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	933	$ 920
Gross Unrealized Gain
Gross Unrealized Loss
Fair Value of Current Assets
Fair Value of Non-Current Assets
Fair Value of Total Assets	$ 933	$ 933

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 4,821,833	$ 4,811,433
Less: accumulated depreciation	(1,767,484)	(1,666,055)
Property and equipment, net	3,054,349	3,145,378
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,509,126	2,509,126
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	2 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	7 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 145,754	145,754
Property and equipment, estimated useful life	7 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 41,898	41,898
Property and equipment, estimated useful life	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 471,505	471,505
Property and equipment, estimated useful life	5 years
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,653,550	$ 1,643,150

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 101,429	$ 174,698

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Professional and consulting fees	$ 280,500	$ 15,000
Research and development	405,000	250,000
CIP- Equipment		279,730
Other	70,535	56,570
Accrued Expenses	$ 756,035	$ 601,300

Members_ Capital (Details Narra

Members’ Capital (Details Narrative) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Preferred Units Class F [Member]
Preferred Units [Line Items]
Preferred units, issued	614,137	3,243,201
Preferred Units Class F [Member] | CTx Board [Member]
Preferred Units [Line Items]
Preferred units, authorized	6,984,985
Issuance of preferred uniits	$ 11.3
Preferred Units Class G [Member]
Preferred Units [Line Items]
Preferred units, issued	614,137	3,243,201
Preferred Units Class G [Member] | CTx Board [Member]
Preferred Units [Line Items]
Preferred units, issued	2,998,184
Preferred units, authorized	12,000,000
Issuance of preferred uniits	$ 6.7

Schedule of Various Distributio

Schedule of Various Distribution Thresholds (Details)	3 Months Ended
	Mar. 31, 2022USD ($)
Distribution Threshold $25 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017	$ 4,753,000
2018
2019
2020
Total	4,753,000
Distribution Threshold $40 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017	125,200
2018	661,525
2019
2020
Total	786,725
Distribution Threshold $75 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017
2018	217,725
2019
2020
Total	217,725
Distribution Threshold $80 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017
2018	22,883
2019
2020	1,476,126
Total	1,499,009
Distribution Threshold $90 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017
2018
2019	377,524
2020
Total	377,524
Distribution Threshold $120 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017
2018
2019	458,924
2020	49,554
Total	508,478
Distribution Threshold $160 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017
2018
2019
2020
2021	357,539
Total	357,539
Distribution Threshold [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017	4,878,200
2018	902,133
2019	836,448
2020	1,525,680
2021	357,539
Total	$ 8,500,000

Profits Interest Plan (Details

Profits Interest Plan (Details Narrative) - Equity Incentive Plan (PIU) [Member] - USD ($) $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Apr. 30, 2021	Mar. 31, 2022	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Stock option, granted			8,500,000
Stock option, issued			8,142,461
Remaining shares issued	357,539
Conversion of stock, amount	$ 8.5
Conversion of stock into common shares	1,158,008
Noncash compensation expense			$ 12.7
General and Administrative Expense [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncash compensation expense			8.2
Selling and Marketing Expense [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncash compensation expense			$ 4.5
Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Vesting period		107 days

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized	240,000,000	240,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Number of shares of common stock issued	11,309,412	11,309,412
Common stock, shares outstanding	11,309,412	11,309,412
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares of common stock issued	4,166,666
Share issued price per share	$ 6
Proceeds from public offering	$ 20.4
Reorganization Merger [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares of common stock issued		7,142,746
Common stock, shares outstanding		7,142,746

Summary of Option Activity (Det

Summary of Option Activity (Details) - 2021 Equity Incentive Plan [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Common stock options, outstanding at Beginning Balance	523,285
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 6
Weighted Average Remaining Contractual Life (Years) Outstanding, Ending	9 years 9 months 10 days	9 years 11 months 8 days
Number of Shares, Granted	342,999
Weighted Average Exercise Price, Granted	$ 1.82
Weighted Average Remaining Contractual Term, Grants	9 years 10 months 28 days
Number of Shares, Exercised
Number of Shares, Forfeitures or expirations
Number of Shares Common stock options, outstanding at Beginning balance	866,284
Weighted Average Exercise Price, Outstanding Ending Balance	$ 4.35
Aggregate intrinsic value	$ 182,900
Shares, Vested and expected to vest
Shares, Exercisable

Schedule of Fair Value Assumpti

Schedule of Fair Value Assumption (Details)	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	1.54%
Weighted-average expected term (in years)	6 years
Expected volatility	1.12%
Expected dividend yield	0.00%

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 181,518
Grant-date fair value of options		$ 5.09
Share-based compensation arrangements aggregate intrinsic value	$ 1.97
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Grant-date fair value of options	1.12
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Grant-date fair value of options	$ 1.16
IPO [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 181,518
2021 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation, description	The number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1st of each year until the expiration of the 2021 Plan, in an amount equal to 5% percent of the total number of shares of our common stock outstanding on December 31st of the preceding calendar year, on a fully diluted basis, unless the board of directors takes action prior thereto to provide that there will not be an increase in the share reserve for such year or that the increase in the share reserve for such year will be of a lesser number of shares of common stock than would otherwise occur.
Unrecognized compensation cost	$ 2,854,519	$ 2,637,895
2021 Equity Incentive Plan [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares common stock options	1,061,526
2021 Equity Incentive Plan [Member] | Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares common stock options	1,927,810

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Federal income tax benefit at statutory rate	$ (1,039,582)
State income tax benefit	(273,757)
Permanent differences	5,665
Change in valuation allowance	1,361,886
Other	(54,212)
Total income tax expense

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Research and development costs	$ 569,826
Unvested stock options	119,333	11,835
Other		4,050
Patents	99,580	90,480
Net operating losses	1,824,223	1,201,974
Other	80,190	49,606
Gross deferred income tax assets	2,693,152	1,357,945
Less: valuation allowance	(2,209,156)	(847,269)
Net deferred income tax asset	483,996	510,676
Accrual to cash	(105,778)	(105,075)
Property and equipment	(378,218)	(405,601)
Gross deferred income tax liabilities	(483,996)	(510,676)
Net deferred tax asset (liability)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Deferred income tax expense benefit	$ 0
Deferred tax assets valuation allowance	$ 2,209,156	$ 847,269

Schedule of Net Loss Per Share

Schedule of Net Loss Per Share Basic And Diluted (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Net loss	$ (5,003,511)	$ (1,333,923)
Weighted average common shares outstanding	11,309,412
Net loss per share, basic and diluted	$ (0.44)

Schedule of Potentially Dilutiv

Schedule of Potentially Dilutive Securities (Details)	3 Months Ended
	Mar. 31, 2022shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,866,282
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	866,284
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,999,998

License Agreement (Details Narr

License Agreement (Details Narrative) - Licensing Agreements [Member]	3 Months Ended
	Mar. 31, 2022USD ($)
CTx-1301 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Accrued milestone payment	$ 250,000
Phase 3 Clinical Trial [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Milestone payment	250,000
New Drug Application [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Milestone payment	250,000
CTx-1301 and CTx-1302 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Milestone payment	250,000
CTx-2103 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Milestone payment	500,000
CTx-2103 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Milestone payment	$ 250,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Related Party Transactions [Abstract]
Rental expense	$ 9,000	$ 9,000